Chhabra Neeti, Malik Sonia
Southend Fertility and IVF Centre, New Delhi, India.
J Hum Reprod Sci. 2018 Oct-Dec;11(4):348-352. doi: 10.4103/jhrs.JHRS_59_17.
Increased circulating insulin levels contribute to hyperandrogenism in polycystic ovarian syndrome (PCOS) which causes a derangement in folliculogenesis, thus contributing to polycystic morphogenesis of the ovaries and a higher than normal anti-Mullerian hormone (AMH). A high AMH is an indicator of either stubborn anovulation or a predictor of ovarian hyperstimulation syndrome. Hence, it is postulated that the use of insulin sensitizers will reduce insulin resistance, hyperandrogenism, and subsequently serum AMH levels and will convert anovulatory cycles to ovulatory.
To study the effect of insulin sensitizers on raised serum AMH levels in infertile women with PCOS.
This was a prospective interventional randomized single tertiary center study.
The study was conducted from August 2015 to April 2016. Infertile patients with PCOS as defined by the Rotterdam criteria with raised AMH (>5 ng/ml) levels were enrolled in the study under strict inclusion and exclusion criteria. The sample size was 105 patients. Cycle regularity, day 2-antral follicle count (AFC), luteinizing hormone, AMH levels, modified Ferriman-Gallwey score (mFGS), and acne score were recorded before starting the intervention. Patients were randomized into three equal groups of 35 each. Group A received metformin alone, Group B metformin plus myoinositol, and Group C only myoinositol. After completion of 3 months of pretreatment, the same parameters were rechecked.
Univariate analysis and Chi-square test were used for statistical analysis.
Of 105 patients, 95 completed treatment and the rest 10 dropped out. There was a reduction in AMH in all groups of insulin sensitizers with significant fall in the metformin only group. Cycle regularity, reduction in AFC, mFGS, and grade of acne were also obtained.
Therapy with insulin sensitizers in PCOS women with raised AMH reduces the AMH levels, converts irregular menstrual cycles to regular, and reduces clinical hyperandrogenism.
循环胰岛素水平升高会导致多囊卵巢综合征(PCOS)患者出现高雄激素血症,进而引起卵泡生成紊乱,促使卵巢发生多囊样形态改变,并使抗苗勒管激素(AMH)高于正常水平。高AMH是顽固无排卵的指标或卵巢过度刺激综合征的预测指标。因此,推测使用胰岛素增敏剂将降低胰岛素抵抗、高雄激素血症,进而降低血清AMH水平,并使无排卵周期转变为有排卵周期。
研究胰岛素增敏剂对PCOS不孕女性升高的血清AMH水平的影响。
这是一项前瞻性干预随机单中心研究。
研究于2015年8月至2016年4月进行。符合鹿特丹标准且AMH水平升高(>5 ng/ml)的PCOS不孕患者在严格的纳入和排除标准下纳入研究。样本量为105例患者。在开始干预前记录月经周期规律性、第2天窦卵泡计数(AFC)、黄体生成素、AMH水平、改良Ferriman-Gallwey评分(mFGS)和痤疮评分。患者被随机分为三组,每组35例。A组单独使用二甲双胍,B组使用二甲双胍加肌醇,C组仅使用肌醇。在完成3个月的预处理后,重新检查相同参数。
采用单因素分析和卡方检验进行统计分析。
105例患者中,95例完成治疗,其余10例退出。所有胰岛素增敏剂组的AMH均有降低,仅二甲双胍组显著下降。月经周期规律性、AFC降低、mFGS和痤疮分级也有改善。
对AMH升高的PCOS女性使用胰岛素增敏剂治疗可降低AMH水平,使不规则月经周期转变为规律周期,并减轻临床高雄激素血症。